Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.

Clinical pharmacology and therapeutics - 1 Mar 1992

Sindrup S H, Brøsen K, Gram L F

Abstract excerpt

Steady-state plasma concentrations of paroxetine were studied at five or more paroxetine dose levels (10 to 70 mg/day) in each of 13 extensive metabolizers of sparteine and at three or four dose levels (10 to 40 mg/day) in each of three poor metabolizers of sparteine, all treated for diabetic neuropathy symptoms. On a dose of 30 mg/day there was a 25-fold variation in steady-state concentrations (25 to 670...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Oxidation-Reduction
Share to Phenotype

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Piperidines

Share to Polymorphism, Genetic

Share to Sparteine

Source

Identifiers

PMID: 1531951
DOI: 10.1038/clpt.1992.24

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.PMID 1531951Read ↗

The relationship between paroxetine and the sparteine oxidation polymorphism.Semantic proximity Read ↗

Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling.Semantic proximity Read ↗

CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.Semantic proximity Read ↗

Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.Semantic proximity Read ↗

Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers.Semantic proximity Read ↗

Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.Semantic proximity Read ↗

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.Semantic proximity Read ↗

The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.Semantic proximity Read ↗

Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.Semantic proximity Read ↗

Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.Semantic proximity Read ↗

Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.Semantic proximity Read ↗

Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.